Table 1.

The PD-1/PD-L1 inhibitors licensed for clinical use or under clinical trials for 1062 NSCLC treatment.

Checkpoint	Blocking agent	IgG isotype and characteristics	Clinical stage	Manufacturer
PD-1	Pembrolizumab (MK3475, Keytruda, lambrolizumab)	Humanized IgG4 mAb	EMA, FDA approved for second-line NSCLC treatment	Merck
	Nivolumab (BMS936558, Opdivo, MDX-1106, ONO-4538)	Fully human IgG4 mAb	FDA approved for first-line and second-line NSCLC	Bristol-Myers Squibb
	MEDI0680 (AMP-514)	Humanized IgG4 mAb	Phase I	Medimmune
	PDR001	Humanized IgG4 mAb	Phase I	Novartis
	REGN2810	Humanized IgG4 mAb	Phase I	Regeneron-Sanofi
PD-L1	Atezolizumab (Tecentriq, MPDL3280A, RG7446)	High-affinity human IgG1	FDA approved for second-line NSCLC	Genentech/Roche
	Durvalumab (MEDI4736, Infinzi)	Human IgG1-κ mAb	FDA approved for treatment of unresectable stage III NSCLC without relapse after platinum-based chemoradiation	MedImmune/AstraZeneca
	BMS-936559 (MDX1105)	Fully high-affinity human IgG4	Phase I	Bristol-Myers Squibb
	Avelumab (Bavencio, MSB0010718C)	Fully human IgG1 mAb	FDA-approved treatment for metastatic MCC	Merck Serono

FDA: Food and Drug Administration; Ig: immunoglobulin; mAb: monoclonal antibody; NSCLC: non-small-cell lung cancer; PD-1: programmed death-1; PD-L1: programmed death-ligand 1; PD-L2: programmed death-ligand 2.